Media Category: Prognosis
ParadigMS publication in NEURON(E) journal: Translating the 2024 McDonald Criteria into Clinical Practice
Source (journal article): NEURON, Vol. 30, #3 (2025), pp. 18–22 (Dutch).
In this article, Christine Lebrun-Frenay, member of the McDonald and ECTRIMS committees and co-founder of the RIS Consortium, reviews the rationale behind the 2024 revision and discusses its practical implications, particularly in asymptomatic patients transitioning from Radiologically Isolated Syndrome (RIS) to Multiple Sclerosis (MS).
This publication reflects ParadigMS’ ongoing commitment to translating evolving diagnostic frameworks into clinically relevant guidance for neurologists.
Key takeaways
The...
Astrocytes and myelin – pathology and pathway
Advances in antibody testing and biomarker-driven diagnostics have reshaped the distinction between Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and MOG antibody-associated disease (MOGAD). Florian Deisenhammer reviews the historical shift from considering NMO a subtype of MS to recognizing NMOSD as a distinct antibody-mediated condition, and outlines how AQP4-IgG and MOG-IgG testing – together with characteristic MRI and CSF patterns – supports more accurate diagnosis. A central message is that these diseases can overlap clinically, but differ...
Astrocytes and myelin – Clinical aspects: available and future treatment
This lecture explains how antibody-mediated pathology translates into clinical phenotypes and treatment strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Melinda Magyari contrasts the core targets, astrocytes (aquaporin-4) in NMOSD versus myelin/oligodendrocytes (MOG) in MOGAD, and shows how these mechanisms drive differences in relapse recovery, long-term disability, and therapeutic priorities. A major emphasis is placed on early antibody testing to avoid misdiagnosis (particularly as Multiple Sclerosis) and...
Translation of 2024 MS criteria for asymptomatic individuals into clinical practice: From RIS to MS
This recording will help you refine your MS diagnostic skills with Christine Lebrun-Frenay led-insights on the 2024 McDonald criteria and practical tools for confident early detection.
Key Insights from the Webinar
The 2024 McDonald revision refines diagnostic clarity in Multiple Sclerosis (MS) while maintaining strong continuity with the 2017 criteria. The update aims to support earlier, more confident diagnosis, particularly for asymptomatic or preclinical cases, and to reduce over-diagnosis in patients with vascular or migraine-related MRI findings. The session highlights how these...
